Ngenla Interactions
There are 437 drugs known to interact with Ngenla (somatrogon), along with 8 disease interactions, and 2 alcohol/food interactions. Of the total drug interactions, 4 are major, 417 are moderate, and 16 are minor.
- View all 437 medications that may interact with Ngenla
- View Ngenla alcohol/food interactions (2)
- View Ngenla disease interactions (8)
Most frequently checked interactions
View interaction reports for Ngenla (somatrogon) and the medicines listed below.
- Actimmune (interferon gamma-1b)
- Adcetris (brentuximab)
- Adcirca (tadalafil)
- Addyi (flibanserin)
- Adzynma (apadamtase alfa, recombinant)
- Aimovig (erenumab)
- Alhemo (concizumab)
- Altuviiio (antihemophilic factor)
- Alyftrek (deutivacaftor / tezacaftor / vanzacaftor)
- ambrisentan
- Amondys 45 (casimersen)
- Amvuttra (vutrisiran)
- Andembry (garadacimab)
- apremilast
- Attruby (acoramidis)
- Aubagio (teriflunomide)
- Augtyro (repotrectinib)
- Austedo XR (deutetrabenazine)
- Bafiertam (monomethyl fumarate)
- Benlysta (belimumab)
- Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
- Bimzelx (bimekizumab)
- Blenrep (belantamab mafodotin)
- Blincyto (blinatumomab)
- bosentan
- Braftovi (encorafenib)
- Breyanzi (lisocabtagene maraleucel)
- Brilinta (ticagrelor)
- Brineura (cerliponase alfa)
- Briumvi (ublituximab)
Ngenla alcohol/food interactions
There are 2 alcohol/food interactions with Ngenla (somatrogon).
Ngenla disease interactions
There are 8 disease interactions with Ngenla (somatrogon) which include:
- active malignancy
- acute critical illness
- diabetic retinopathy
- Prader-Willi Syndrome
- intracranial hypertension
- scoliosis
- diabetes mellitus
- Turner syndrome
Report options
QR code containing a link to this page
More about Ngenla (somatrogon)
- Ngenla consumer information
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: growth hormones
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
